NEW YORK (GenomeWeb) – Citing unattractive terms, molecular diagnostics firm AltheaDx has withdrawn its planned initial public offering. 

The San Diego-based firm said in a document filed with the US Securities and Exchange Commission on Monday that it chose not to pursue its IPO at this time as the "terms currently obtainable in the public marketplace are not sufficiently attractive to [the company] to warrant proceeding with the public offering." 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.